Invokana Sales Figure Witness a Dip
Invokana Sales Figure Witness a Dip
Introduction
According to the fourth quarter 2017 sales earnings report released by J&J, Invokana made $262 million which was a 29% dip when compared to the previous reports. The low figures are reasoned to be due to the growing competition and awareness of the side-effects associated with this the Type 2 diabetes medication.
Comments
Latest News
New Front Emerges in Fight Against Synthetic Opioids
Categories: Opioids
The U.S. opioid crisis has already claimed hundreds of thousands of lives, with fentanyl standing out as one of the deadliest substances. Now the leading cause of death among Americans aged 18 to 44, fentanyl has become synonymous with overdose…
Exactech to Pay $8M to Settle Defective Knee Implant Suit
Categories: Attune Knee System
Medical device maker Exactech has agreed to an $8 million settlement to resolve allegations that it hid defects in a widely used line of artificial knee implants.
The implants have been linked to thousands of patient injuries and sparked…
Talcum Powder Cancer Settlement Talks Begin Sept. 4
Categories: Talcum
Representatives of Johnson & Johnson (J&J) and attorneys for tens of thousands of plaintiffs involved in talcum powder lawsuits are scheduled to meet in September 2025 in an…